AutoCAD engineering
Concept geometry, stage views and engineering drawings — a question turned into something you can inspect and measure. Fabrication readiness still requires validation.
Every study this theory rests on, with its PubMed ID and what it actually found. 14 papers. Read the findings, not the labels.
A theory is only as good as the record you can check. These are not studies we went looking for to support a conclusion — they are the papers cited throughout this project's work, pulled back out and re-verified one at a time. Each one is linked to PubMed. Every PMID below was checked for retraction status on 4 November 2026. Where a paper we had logged turned out to be retracted, it was removed from the citation list and the removal was recorded rather than hidden.
Each of these is a published finding on an agent that is already approved, already cheap, or already on a supermarket shelf. The moxidectin case shows the pattern: three independent groups, seven years, an approved off-patent drug, and no registered human cancer trial. Every entry below is a candidate for the same question — who is assessing this, what did they find, and where can anyone inspect it?
One paper we had logged — a case series of three stage IV patients self-administering fenbendazole, published in Case Reports in Oncology in 2025 — was withdrawn by the journal in 2026. The withdrawal notice states no reason. Its entire text is “[This retracts the article DOI: 10.1159/000546362.]” We are not going to pretend the cases were never reported, and we are not going to lean on them either. A withdrawal without a stated reason is an exercise of editorial authority, not an argument about data, and it settles nothing in either direction. The theory below does not rest on it — which is precisely why we can say so plainly.
The cation accumulates across the membrane potential by electrophoresis. No receptor in the mechanism at all — the molecule is pulled by a voltage. This is Family B's entire premise, published twenty years before we used it.
A substance with no receptor, no pocket and no binding affinity reduced spontaneous metastasis in vivo. If a proton gradient alone can do that, the active variable is not molecular shape.
Peroxide is a messenger, not exhaust. In Science, in 2006. Our claim that the cell reads a redox quantity rather than a shape is not a fringe reading — it is the standard one.
The title is the mechanism. A thiol-based sensor — detection by reactive cysteine, not by geometry. This is why broccoli and a peroxide can speak to the same system.
Sulforaphane, isolated and characterised in 1992. The broccoli limb is thirty-four years old and was never controversial — only unconnected to the rest.
Gold closes the peroxide drain. An arthritis drug from 1985, acting on the same quantity as an antimalarial and a wormer.
Starve the cell of cystine and you starve its glutathione. Another unrelated drug, same pool.
"Multitargeted" is the conventional literature noticing the problem without naming it. A drug that hits many targets may instead be hitting one state.
The paper also reports interference with glucose uptake — two effects from one compound, both of which land on metabolic and redox tone.
An inhibitor built for an enzyme that exists only inside a virus, killing human cancer cells. Under lock-and-key this is inexplicable. Under ER overload it is arithmetic: oxidative protein folding makes one H2O2 per disulfide bond.
A peroxide bridge delivered to ferrous iron. The molecule literally carries the oxidant to the metal.
The authors noted no earlier study had examined moxidectin for cancer at all.
A second group, a different mechanism, the same drug.
A third group, August 2025, with tumour suppression in an intracranial mouse model. Approved for human use since 2018, WHO-listed, off patent, cheap — and still no registered human cancer trial.
One discipline runs underneath all of it: computational engineering — designing the thing completely, and proving out what you can, before anyone cuts metal or runs a reaction. It is the same craft whether the object is a bracket or a molecule. Only the units change.
Concept geometry, stage views and engineering drawings — a question turned into something you can inspect and measure. Fabrication readiness still requires validation.
The lattice between the two worlds: geometry that has to obey physics before it is worth costing, let alone building.
The same discipline applied to chemistry — scaffolds, conjugates and the design rationale for why a given structure should be made before anyone makes it.
Every structure parsed, sanitised and reported with its computed property set: isomeric SMILES, mass, lipophilicity, polar surface area, stereocentres. Computed, never quoted.
Our intention is plain: to own this field — computational engineering from the drawing to the molecule. Not by holding patents, but by being the group that does the work in the open, publishes its own corrections, and is the best in the world at deciding what is worth building next.
Computational designs only. Nothing described here has been synthesised, assayed or administered, and every property is a computed descriptor rather than a measurement. Fabrication and clinical readiness require validation that happens outside this factory.